Tonix Pharmaceuticals Intends To Offer And Sell Shares Of Its Common Stock Or Pre-funded Warrants In Lieu Thereof

All of the securities to be sold in the offering are to be offered by Tonix. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness.